Consideration on Relationship between Developmental Strategy of Additional Indication and Price Strategy for Anticancer Drug in Japan - 2nd report -

○Ayano Okabe

4:15 PM - 4:27 PM

[28V09-pm16S] Consideration on Relationship between Developmental Strategy of Additional Indication and Price Strategy for Anticancer Drug in Japan - 2nd report -

○Ayano Okabe¹, Manabu Akazawa², Hideki Maeda¹ (1. Dept. Regulatory Science, Meiji Pharm Univ., 2. Dept. Public Health and Epidemiology, Meiji Pharm Univ.)

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.

Presentation information

[28V09-pm] 薬剤疫学/医療経済学/その他

[28V09-pm16S] Consideration on Relationship between Developmental Strategy of Additional Indication and Price Strategy for Anticancer Drug in Japan - 2nd report -

Password